Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2. 1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI.
|Titolo:||Risk factors for lipodystrophy in the CISAI cohort|
|Parole Chiave:||Drug Therapy, Combination ; HIV Protease Inhibitors ; Age Factors ; Risk Factors ; Humans ; Lipodystrophy ; Cohort Studies ; Adult ; Acquired Immunodeficiency Syndrome ; Antiretroviral Therapy, Highly Active ; Male ; Female|
|Settore Scientifico Disciplinare:||Settore MED/40 - Ginecologia e Ostetricia|
|Data di pubblicazione:||nov-2003|
|Digital Object Identifier (DOI):||10.1016/j.biopha.2003.06.002|
|Appare nelle tipologie:||01 - Articolo su periodico|